Microbix’s Clot-Buster Drug Project Advances
By Microbix Admin | March 14, 2024
Microbix Unveils Test Controls for Head and Neck Cancer
By Microbix Admin | March 11, 2024
Microbix’s Virtual AGM 2024
By Microbix Admin | February 21, 2024
Microbix Reports Record Results for Q1 Fiscal 2024
By Microbix Admin | February 14, 2024
Microbix Schedules Release of Results for Q1 Fiscal 2024
By Microbix Admin | February 7, 2024
Microbix Unveils Test Control for Gastric Ulcer Disease Pathogen
By Microbix Admin | February 6, 2024
Microbix Achieves Further QAPs Sales Record
By Microbix Admin | January 3, 2024
Microbix Reports Results for Q4 & Full-Year Fiscal 2023
By Microbix Admin | December 21, 2023
Microbix & Seegene USA Jointly Enhancing Lab Test Accuracy
By Microbix Admin | December 14, 2023
Microbix & BioGX Collaborate on real-time PCR Assays & Controls
By Microbix Admin | December 7, 2023
Microbix Announces Initiation of Normal Course Issuer Bid
By Microbix Admin | December 6, 2023
Microbix Presenting at Florida Capital Event Conference
By Microbix Admin | November 17, 2023
Microbix Clot-Buster Drug Fully-Funded For Return to U.S. Market
By Microbix Admin | November 16, 2023
Microbix & Ulisse Biomed Collaborate on HPV Controls & Assays
By Microbix Admin | November 10, 2023
Battling Flu Season: Quality Control and Microbix
By Microbix Admin | November 8, 2023
Microbix QAPs Supporting HPV Testing in Ireland
By Microbix Admin | October 27, 2023
Season 1 Episode 5: Diagnostics Beyond the Lab: Bridging Policy and Innovation for a Healthier Tomorrow
By Microbix Admin | October 26, 2023
Episode 3: Diagnostics: Beyond the lab – Self-Collection with Copan Italia
By Microbix Admin | October 21, 2023
Episode 5: Diagnostics Beyond the Lab: Bridging Policy and innovation for a healthier tomorrow
By Microbix Admin | October 20, 2023
Microbix Presenting at Muskoka Capital Conference
By Microbix Admin | September 29, 2023
Microbix Achieves New QAPs Sales Record
By Microbix Admin | September 27, 2023
Guest for Season 1- Episode 5: Diagnostics Beyond the Lab
By Microbix Admin | September 26, 2023
Microbix Honours the Passing of its Founder William J. Gastle – 1948 to 2023
By Microbix Admin | September 13, 2023
Microbix Reports Results for Q3 Fiscal 2023
By Microbix Admin | August 10, 2023
Microbix Successfully Upgrades Logistics Software Systems
By Microbix Admin | August 7, 2023
Microbix Presents Results of STI Test Controls at AACC
By Microbix Admin | July 24, 2023
Microbix QAPs Supporting HPV Testing Across The Netherlands
By Microbix Admin | July 5, 2023
Respiratory virus multiplex formulations desiccated on Copan’s FLOQSwab© for use as cross-platform compatible EQA samples – and laboratory Quality Control
By Microbix Admin | June 20, 2023
Microbix & Labquality Create Novel Testing Accreditation Program
By Microbix Admin | June 20, 2023
Evaluating the performance of STI POC assays using Swab format Quality Controls
By Microbix Admin | June 18, 2023
Performance of NAAT that detect MGEN using Swab Quality Controls
By Microbix Admin | June 18, 2023
The Essential Role of Multiplex Quality Control in In Vitro Diagnostics for Infectious Diseases
By Microbix Admin | May 23, 2023
Enhancing STI testing accuracy and reliability with Microbix’s External Quality Controls
By Microbix Admin | May 16, 2023
Microbix Secures Funded Drug Commercialization Agreement
By Microbix Admin | May 16, 2023
Microbix Reports Results for Q2 Fiscal 2023
By Microbix Admin | May 11, 2023
Trichomonas Vaginalis: Why Early Detection is Crucial
By Microbix Admin | May 9, 2023
The Lowdown on STI Testing: What You Need to Know
By Microbix Admin | May 2, 2023
The Silent Killer: Exploring the Alarming Rise of Antimicrobial Resistance
By Microbix Admin | April 25, 2023
Episode 4: Diagnostics Beyond the Lab: Ensuring Patient Health through EQA
By Microbix Admin | April 24, 2023
Microbix’s Multiplex Quality Control for STI Diagnosis
By Microbix Admin | April 18, 2023
Syphilis on the Rise in Canada: A Call to Action for Public Health and Individuals
By Microbix Admin | April 10, 2023
Breaking the Stigma: Managing STIs for Better Sexual Health
By Microbix Admin | April 3, 2023
Meet our Guests- Episode 4: Ensuring Patient health through EQA
By Microbix Admin | March 29, 2023
The Importance of External Quality Assessment (EQA) in Laboratory Testing
By Microbix Admin | March 29, 2023
Revolutionizing Pandemic Preparedness with Self-Collection
By Microbix Admin | March 20, 2023
Diagnostics Explained: AMR
By Microbix Admin | February 21, 2023
CEM Muskoka – September 23-25
By Microbix Admin | February 8, 2023
Upcoming Events 2023
By Microbix Admin | February 2, 2023
Upcoming Events: Coming Soon
By Microbix Admin | January 27, 2023
Blog: Episode 3
By Microbix Admin | January 13, 2023
Blog: Episode 2
By Microbix Admin | January 10, 2023
Blog: Episode 1
By Microbix Admin | January 5, 2023
2022 Q2 Financial Report
By Microbix Admin | November 11, 2022
High-Risk HPV Quality Controls are Needed to Uphold Clinical Laboratory Quality Standards
By Microbix Admin | November 10, 2022
Emerging requirements for infectious disease IVD quality control material
By Microbix Admin | November 10, 2022
Expected stability of REDx™FLOQ © SARS-CoV-2 Swab Positive Control and REDx™FLOQ© SARS-CoV-2 Swab Negative Control in various sample transport media and storage conditions
By Microbix Admin | November 9, 2022
2022 Q3 Financial Report
By Microbix Admin | November 9, 2022
Use of REDx™FLOQ © SARS-CoV-2 Ag Swab Positive Control and REDx™FLOQ© Respiratory Swab Negative Control as Quality Control by POC devices in various testing conditions
By Microbix Admin | November 8, 2022
Novel Cross-Platform High-Risk (hr) HPV NAAT Positive Controls for Use in L1 and E6/E7 Targeted Nucleic ACID (DNA and RNA) Detection Methods
By Microbix Admin | November 8, 2022
Cross-Platform High-Risk (hr) Low Occurrence HPV NAAT Positive Samples of Use in Nucleic Acid Detection Testing as Prospective External Quality Assessment Samples – and User Defined Quality Controls
By Microbix Admin | November 8, 2022
Performance of full and extended genotyping assays using a new high-risk HPV multiplex panel
By Microbix Admin | November 7, 2022
Respiratory virus multiplex formulations desiccated on Copan’s FLOQSwab® for use as cross-platform compatible EQA samples and laboratory Quality Control
By Microbix Admin | November 6, 2022
Novel Mycoplasma genitalium (Mgen) and AMR Mgen A2059G Materials for use in a Cross-Platform NAAT Quality Control
By Microbix Admin | November 6, 2022
Simulated swab specimens for whole workflow quality control of SARS-CoV-2 molecular diagnostic testing
By Microbix Admin | November 5, 2022
2022 Q1 Financial Report
By Microbix Admin | November 5, 2022
Advanced SARS-CoV-2 Variants of Concern (VOC) whole-genome materials for use as verification, external quality assessment (EQA) and prospective quality control samples
By Microbix Admin | November 4, 2022
Episode 2: Diagnostics: Beyond the Lab – AMR MGEN with Colin Denver from SpeeDx
By Microbix Admin | November 4, 2022
Advanced SARS-CoV-2 nucleocapsid protein swab-based formulation for use as a cross-platform EQA sample and as a prospective Quality Control
By Microbix Admin | November 3, 2022
Novel neutralizing anti-S1 SARS-CoV-2 human monoclonal antibody formulation for use as a cross-platform EQA sample and prospective quality controls
By Microbix Admin | November 2, 2022
Novel SARS-CoV-2 Full-Genome Material for Use in a Swab-Based Formulation as a Multi-Platform NAAT Quality Control
By Microbix Admin | November 1, 2022
Episode 1: Diagnostics: Beyond the lab – HPV with Larry Vaughn, BD and Dr. Cathy Popadiuk
By Microbix Admin | November 1, 2022
MBX Investor Update Webinar
By Microbix Admin | October 31, 2022
AGM Presentation – March 2022
By Microbix Admin | October 31, 2022
AGM PRESENTATION 2022
By Microbix Admin | October 31, 2022
Microbix Corporate Presentation – September 2022
By Microbix Admin | October 31, 2022
Microbix Corporate Presentation – October 2022
By Microbix Admin | October 31, 2022
Novel Cross-Platform High-Risk (hr) HPV NAAT Positive Controls for Use in L1 and E6 / E7 Targeted Nucleic ACID (DNA and RNA) Detection Methods
By Microbix Admin | October 24, 2022
Cross-Platform High-Risk (hr) Low Occurrence HPV NAAT Positive Samples of Use in Nucleic Acid Detection Testing as Prospective External Quality Assessment Samples and User Defined Quality Control
By Microbix Admin | October 24, 2022
Emerging requirements for infectious disease IVD quality control materials
By Microbix Admin | October 18, 2022
CEM Florida – November 11-13
By Microbix Admin | July 25, 2022
About us
By Microbix Admin | June 22, 2022
2022 AMMI Canada-CACMID Annual Conference – April 5-8
By Microbix Admin | March 3, 2022
2022 EUROGIN International Multidisciplinary HPV Congress – April 10-13
By Microbix Admin | March 3, 2022
Why We Need To Test COVID-19 Tests
By Microbix Admin | March 3, 2021
Microbix Discloses New Products, Sales, And Capacity
By Microbix Admin | October 29, 2020
Microbix Creates Further COVID-19 Quality Assessment Products
By Microbix Admin | October 20, 2020
Ontario Helps Microbix Ensure Provincial COVID Testing Capacity
By Microbix Admin | October 13, 2020
Microbix Presenting COVID-19 Product Results To Industry
By Microbix Admin | September 22, 2020
Microbix Announces Extension Of Warrant Expiry Dates
By Microbix Admin | September 17, 2020
Microbix Announces Board Changes
By Microbix Admin | September 15, 2020
Microbix’s REDx™ Controls Attain Australian TGA Registration
By Microbix Admin | September 10, 2020
Q3 Fiscal 2020
By Microbix Admin | August 14, 2020
Curious To See How We Perform A COVID Test?
By Microbix Admin | July 21, 2020
Microbix Shares Become Available For U.S. Investors
By Microbix Admin | July 14, 2020
Microbix COVID-19 QAPs Attain EU “CE Mark” Registration
By Microbix Admin | June 5, 2020
Microbix Announces Quality Products Distribution Agreement – Appointment of Medical Supply Company of Ireland
By Microbix Admin | June 4, 2020
Microbix Engaged To Develop & Supply Custom QAPs™
By Microbix Admin | June 2, 2020
Microbix Expanding QAPs™ Production Capacity
By Microbix Admin | May 27, 2020
Microbix Achieves Full Utilization Of Its Bioreactors
By Microbix Admin | May 19, 2020
Microbix Announces Quality Products Distribution Agreement – Appointment of Labquality Oy of Finland for 7 Countries
By Microbix Admin | May 15, 2020